Trials / Enrolling By Invitation
Enrolling By InvitationNCT05777993
A Study to Provide Continued Access to Mitapivat for Participants Who Previously Completed an Agios-Sponsored Mitapivat Study
A Rollover Study to Provide Continued Access to Mitapivat for Participants Who Previously Completed an Agios-Sponsored Mitapivat Study
- Status
- Enrolling By Invitation
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 6 (estimated)
- Sponsor
- Agios Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to provide continued access to mitapivat for participants who completed an Agios-sponsored mitapivat study (antecedent) and do not have commercial access to mitapivat.
Detailed description
Participants will continue the mitapivat dose regimen that they were receiving at the final visit of their antecedent study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mitapivat | Tablets |
Timeline
- Start date
- 2023-07-06
- Primary completion
- 2029-08-01
- Completion
- 2029-08-01
- First posted
- 2023-03-21
- Last updated
- 2026-03-30
Locations
4 sites across 2 countries: Canada, Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05777993. Inclusion in this directory is not an endorsement.